Click for quick access:
Our Diagnostics and Your Diagnosis
Non-invasive tests that use mRNA to detect cancer in real-time, and help tailor and monitor treatment.
Tissue biopsies, conventional biomarkers, and imaging, such as CT scans or MRIs, provide important information that can lead to preliminary diagnoses of neuroendocrine cancer or prostate cancer. However, there are drawbacks, as they can be invasive, time-consuming, or lacking in accuracy and specificity.
Our diagnostics use mRNA—the body’s cellular messaging system—to identify tumor activity and to better understand the disease state of cancer. mRNA is found in an easily obtained blood sample, can be analyzed and reported on within 48 hours, and offers unmatched accuracy (>95% for NET, >90% for Prostate) and specificity (>90% for NET, >95% for Prostate).
Blood mRNA and Your Cancer Diagnosis
Since our founding, we’ve focused on measuring mRNA for our tests. It is a proven diagnostic as the first mRNA assay was utilized in 1998. It contains powerful molecular information that, when used by our AI-driven analytics, provides significant insight into disease activity*. It’s robust and stable, and when combined with our sampling buffer, it transports well from the collection site to our lab.
Well-Researched and Expanding Usage
Our approach to cancer diagnostics—using mRNA assessment with the help of artificial intelligence and multianalyte analysis—is backed by more than 60 peer-reviewed articles. Additionally, leading oncologists in medical centers across the U.S. have used the NETest over 10,000 times.
*Disease activity is defined as the calculated risk of highly active disease as measured by an algorithm based on gene expression data. Test results should be used in conjunction with standard clinical assessment.
About Our Science
The diagnostics offered by Wren Laboratories, which include a blood-based neuroendocrine cancer test (NETest), a PRRT treatment predictor quotient (NETest PPQ), a saliva-based Covid-19 test, and a soon-to-be-available prostate cancer test (PROSTest), are all based on the assessment of mRNA found in effortlessly-obtained body fluids: blood and saliva. We use state-of-the-art standardized laboratory techniques to process these liquid biopsies before assessing them with a suite of gene assays and proprietary algorithms we have developed.
mRNA Molecular Testing
Our molecular cancer diagnostics are unsurpassed in accuracy while delivering high levels of sensitivity and specificity to minimize incorrect diagnoses.
Understand the disease state of the neuroendocrine tumor – is it growing slowly or aggressively?
PPQ is an accurate (>96%) predictor of patient response to PRRT
NETest Fast Facts
The NETest helps you know more about a Neuroendocrine Tumor Diagnosis
Has been the subject of over 60 academic papers, peer-reviewed studies, and articles in medical journals.
Helps oncologists and patients manage and monitor treatment and quickly detect disease recurrence.
The NETest has been commercially available for almost 10 years and has been utilized over 10,000 times.
We have developed a multi-mRNA liquid biopsy biomarker assay that can help detect and define the molecular pathology of prostate cancer with a simple blood test.
Our blood-based PROSTest is a non-invasive prostate biopsy equivalent and can accurately detect, with greater than 90% confidence, the presence of prostate cancer gene markers in an easily obtained blood sample. Like our NETest, this biomarker assay plays a crucial role in characterizing the molecular pathology of prostate cancer for treatment guidance and monitoring.
The PROSTest is currently an “Investigational-use” diagnostic not commercially available to the general public. For more informational about it, please email us.
Benefits and Differentiators
Far Less Invasive: unlike a tissue biopsy, which relies on harvested prostate tissue, our diagnostic is based on a drop of blood.